Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$73.90 USD
-0.86 (-1.15%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $73.87 -0.03 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Axsome Therapeutics, Inc. [AXSM]
Reports for Purchase
Showing records 81 - 100 ( 177 total )
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-12 Phase 3 Narcolepsy Trial Initiated on Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-07 New Drug Application Accepted for FDA Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-05 Fears Appear Overblown; 2Q21 Financials; Reducing PT to $180
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fibromyalgia Candidate Regulatory Submission Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-07 Regulatory Submission Imminent; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-05 New Drug Application Accepted With Priority Review; Raising PT to $225
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department